Arrayit Readies Ovarian Cancer Dx for FDA OK, Launches into Full Commercialization Mode

In addition to its OvaDx test, which Arrayit said could be ready to hit the market during the third quarter, the company is developing tests for Parkinson's disease and prostate cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.